Placebo-controlled trial of safety and efficacy of intraoperative controlled delivery by biodegradable polymers of chemotherapy for recurrent gliomas. The Polymer-brain Tumor Treatment Group - PubMed (original) (raw)
Clinical Trial
. 1995 Apr 22;345(8956):1008-12.
doi: 10.1016/s0140-6736(95)90755-6.
Affiliations
- PMID: 7723496
- DOI: 10.1016/s0140-6736(95)90755-6
Free article
Clinical Trial
Placebo-controlled trial of safety and efficacy of intraoperative controlled delivery by biodegradable polymers of chemotherapy for recurrent gliomas. The Polymer-brain Tumor Treatment Group
H Brem et al. Lancet. 1995.
Free article
Abstract
Chemotherapy for brain tumours has been limited because of difficulty in achieving adequate exposure to the tumour without systemic toxicity. We have developed a method for local sustained release of chemotherapeutic agents by their incorporation into biodegradable polymers. Implantation of the drug-impregnated polymer at the tumour site allows prolonged local exposure with minimal systemic exposure. We conducted a randomised, placebo-controlled, prospective study to evaluate the effectiveness of biodegradable polymers impregnated with carmustine to treat recurrent malignant gliomas. In 27 medical centres, 222 patients with recurrent malignant brain tumours requiring re-operation were randomly assigned to receive surgically implanted biodegradable polymer discs with or without 3.85% carmustine. Randomisation balanced the treatment groups for all of the prognostic factors examined. Median survival of the 110 patients who received carmustine polymers was 31 weeks compared with 23 weeks for the 112 patients who received only placebo polymers (hazard ratio = 0.67, p = 0.006, after accounting for the effects of prognostic factors). Among patients with glioblastoma, 6-month survival in those treated with carmustine-polymer discs was 50% greater than in those treated with placebo (mortality = 32 of 72 [44%] vs 47 of 73 [64%], p = 0.02). There were no clinically important adverse reactions related to the carmustine polymer, either in the brain or systemically. Interstitial chemotherapy delivered with polymers directly to brain tumours at the time of surgery seems to be a safe and effective treatment for recurrent malignant gliomas.
Comment in
- Treatment for glioma.
Brewin TB. Brewin TB. Lancet. 1995 Jun 17;345(8964):1571. doi: 10.1016/s0140-6736(95)91117-0. Lancet. 1995. PMID: 7791456 No abstract available.
Similar articles
- Interstitial chemotherapy with drug polymer implants for the treatment of recurrent gliomas.
Brem H, Mahaley MS Jr, Vick NA, Black KL, Schold SC Jr, Burger PC, Friedman AH, Ciric IS, Eller TW, Cozzens JW, et al. Brem H, et al. J Neurosurg. 1991 Mar;74(3):441-6. doi: 10.3171/jns.1991.74.3.0441. J Neurosurg. 1991. PMID: 1993909 Clinical Trial. - Biodegradable polymers for controlled delivery of chemotherapy with and without radiation therapy in the monkey brain.
Brem H, Tamargo RJ, Olivi A, Pinn M, Weingart JD, Wharam M, Epstein JI. Brem H, et al. J Neurosurg. 1994 Feb;80(2):283-90. doi: 10.3171/jns.1994.80.2.0283. J Neurosurg. 1994. PMID: 8283268 - Dose escalation of carmustine in surgically implanted polymers in patients with recurrent malignant glioma: a New Approaches to Brain Tumor Therapy CNS Consortium trial.
Olivi A, Grossman SA, Tatter S, Barker F, Judy K, Olsen J, Bruce J, Hilt D, Fisher J, Piantadosi S; New Approaches to Brain Tumor Therapy CNS Consortium. Olivi A, et al. J Clin Oncol. 2003 May 1;21(9):1845-9. doi: 10.1200/JCO.2003.09.041. J Clin Oncol. 2003. PMID: 12721262 Clinical Trial. - Local treatment of malignant brain tumors using implantable chemotherapeutic polymers.
Gallia GL, Brem S, Brem H. Gallia GL, et al. J Natl Compr Canc Netw. 2005 Sep;3(5):721-8. doi: 10.6004/jnccn.2005.0042. J Natl Compr Canc Netw. 2005. PMID: 16194460 Review. - Polymers to treat brain tumours.
Brem H. Brem H. Biomaterials. 1990 Nov;11(9):699-701. doi: 10.1016/0142-9612(90)90030-t. Biomaterials. 1990. PMID: 2090306 Review.
Cited by
- Updates in intraoperative strategies for enhancing intra-axial brain tumor control.
Wu A, Wu JY, Lim M. Wu A, et al. Neuro Oncol. 2022 Nov 2;24(Suppl 6):S33-S41. doi: 10.1093/neuonc/noac170. Neuro Oncol. 2022. PMID: 36322098 Free PMC article. Review. - Glioblastoma multiforme: Molecular characterization and current treatment strategy (Review).
Zhang X, Zhang W, Cao WD, Cheng G, Zhang YQ. Zhang X, et al. Exp Ther Med. 2012 Jan;3(1):9-14. doi: 10.3892/etm.2011.367. Epub 2011 Oct 18. Exp Ther Med. 2012. PMID: 22969836 Free PMC article. - Polifeprosan 20, 3.85% carmustine slow-release wafer in malignant glioma: evidence for role in era of standard adjuvant temozolomide.
Kleinberg L. Kleinberg L. Core Evid. 2012;7:115-30. doi: 10.2147/CE.S23244. Epub 2012 Oct 26. Core Evid. 2012. PMID: 23118709 Free PMC article. - Re-do craniotomy for recurrent glioblastoma.
Morsy AA, Ng WH. Morsy AA, et al. CNS Oncol. 2015;4(2):55-7. doi: 10.2217/cns.15.4. CNS Oncol. 2015. PMID: 25768328 Free PMC article. No abstract available. - Highly penetrative, drug-loaded nanocarriers improve treatment of glioblastoma.
Zhou J, Patel TR, Sirianni RW, Strohbehn G, Zheng MQ, Duong N, Schafbauer T, Huttner AJ, Huang Y, Carson RE, Zhang Y, Sullivan DJ Jr, Piepmeier JM, Saltzman WM. Zhou J, et al. Proc Natl Acad Sci U S A. 2013 Jul 16;110(29):11751-6. doi: 10.1073/pnas.1304504110. Epub 2013 Jul 1. Proc Natl Acad Sci U S A. 2013. PMID: 23818631 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical